Efficacy and safety of factor VIII/von Willebrand factor concentrate (Haemate-P®) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand's disease

Haematologica

Volumn 88, Issue 11, 2003, Pages 1279-1283

  Franchini, Massimo ^a,e   Rossetti, Gina ^b   Tagliaferri, Annarita ^c   Pattacinni, Corrado ^c   Pozzoli, Donatella ^c   Lippi, Giuseppe ^d   Manzato, Franco ^d   Bertuzzo, Daniela ^a   Gandini, Giorgio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e OSPEDALE POLICLINICO   (Italy)

Author keywords

Factor VIII von Willebrand factor concentrate; Haemate P ; Surgery; Von Willebrand's disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ADULT; AGED; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PERIODONTAL DISEASE; PEROPERATIVE CARE; POSTOPERATIVE COMPLICATION; SIDE EFFECT; SUBSTITUTION THERAPY; THROMBOSIS; TOOTH EXTRACTION; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION; FACTOR VIII; FEMALE; HEMORRHAGE; HUMANS; ITALY; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PUNCTURES; SAFETY; THROMBOPHILIA; TOOTH EXTRACTION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0344823956     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand disease. Blood 1987;69:454-9.
2. Federici AB, Castaman G, Mannucci PM, for the Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002;8:607-21.
3. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001;97:1915-9.
4. Mannucci PM, Federici AB. Management of inherited von Willebrand disease. Best Pract Res Clin Haematol 2001;14:455-62.
5. Lusher JM. Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP - a survey of European physicians. Haemophilia 1998;4:11-4.
6. Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002;99:450-6.
7. Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi GM, Musso R, et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002;8:761-7.
8. Lubetsky A, Martinowitz U, Luboshitz J, Kenet G, Keller N, Tamarin I. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriology safety, pharmacokinetic analysis and clinical experience. Haemophilia 2002;8:622-8.
9. Scharrer I, Vigh T, Aygören-Pürsüen E. Experience with Haemate P in von Willebrand's disease in adults. Haemostasis 1994;24:298-303.
10. Berntorp E, Nilsson IM. Use of high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease. Vox Sang 1989;56:212-7.
11. Dobrovska A, Krzensk U Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998;4:33-9.
12. Blanchette V, Israels SJ, Akabutu J, Bergman GE. Report of the efficacy and safety of Haemate P in Canadian von Willebrand disease (vWD) patients. Thromb Haemost 1997;77 Suppl:513[abstract].
13. Ewenstein BM, Gill JC, Thompson A, Xie F, Mueller-Velten G, Swhwartz BA, for the Humate-P Study Group. Treatment of von Willebrand disease (vWD) in patients with urgent life- or limb-threatening bleeding or emergent surgery with Humate-P (factor VIII/vWF concentrate). Haemophilia 2000;6:227 [abstract].
14. Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Müller HG, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia 1998;4:25-32.
15. Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, et al. Safety and efficacy of continuous infusion of a combined factor VIII - von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost 1999;81:229-33.
16. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002;87:224-30.